<?xml version="1.0" encoding="UTF-8"?>
<p>Duloxetine was a norepinephrine and serotonin reuptake inhibitor developed by Eli Lilly &amp; Company and marketed as Cymbalta in August 2004. Its prime intention was to treat major depressive disorder [
 <xref rid="B56-viruses-12-01058" ref-type="bibr">56</xref>]. However, serotonin and norepinephrine are also known to exhibit excitatory effects on urethral sphincter motor neurons, thereby increasing urethral resistance. With a series of preclinical studies conducted by Eli Lilly, the aforementioned hypothesis came to a fruitful outcome. The drug can now be used to treat stress urinary incontinence (SUI), a state portrayed by occasional loss of urine due to weakening of pelvic muscles, urinary sphincter or other factors such as childbirth and prostatectomy. SUI commonly manifests its symptoms during occasions that cause unexpected increases in intra-abdominal pressure such as laughter, sneezing or coughing. This remarkable finding has led to the rapid development of Duloxetine, wherein the year 2004, 2008 and 2010, the drug was approved by the FDA for diabetic peripheral neuropathic pain (DPNP), fibromyalgia and chronic musculoskeletal pain treatment, respectively [
 <xref rid="B57-viruses-12-01058" ref-type="bibr">57</xref>,
 <xref rid="B58-viruses-12-01058" ref-type="bibr">58</xref>]. As of the year 2011, Duloxetine has generated more than $9 billion in revenue.
</p>
